ClinicalTrials.gg
RecruitingNCT06967480Updated Feb 5, 2026

Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis

An observational study in Generalized Myasthenia Gravis and Anti-AChR Antibody Positive, sponsored by Alexion Pharmaceuticals, Inc.. Recruiting at 23 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-05.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Observational

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Myasthenia Gravis by AstraZeneca — 8 open to participants now, 11 under way, 4 of them phase 3. Myasthenia Gravis · AstraZeneca.

Started
2025
with 3 others
Observational
6 of 19
5 open now
Primary completion
2027-06
later than 3 of 10 live
Registered
16th of 19
by date

Among the 19 studies in Myasthenia Gravis by AstraZeneca, this one is one of 4 that started in 2025, is one of 6 observational ones, reaches primary completion later than 3 of the 10 other live ones, and was the 16th registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

8 of the 19 studies in Myasthenia Gravis by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Myasthenia Gravis by AstraZeneca, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the effectiveness of Ravulizumab in improving MG-ADL in an early-stage AChR+ gMG population.

03

Conditions studied

  • Generalized Myasthenia Gravis
  • Anti-AChR Antibody Positive

Browse trials for

Keywords

  • Anti-AChR Antibody-Positive
  • Generalized Myasthenia Gravis
  • gMG
  • Ravulizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with anti-AChR antibody positive, generalized, myasthenia gravis elegible to Ravulizumab treatment with a disease duration from onset equal or less than 3 years.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of MG confirmed by:

    • History of a positive serologic test for anti-AChR antibodies, and
    • One of the following:

      • History of abnormal neuromuscular transmission test demonstrated by singlefibre electromyography or repetitive nerve stimulation
      • History of positive anticholinesterase test (e.g., edrophonium chloride test); or
      • Patient demonstrated improvement in MG signs on oral cholinesterase inhibitors, as assessed by the treating physician
  • Disease duration from MG onset ≤ 3 years before T-4 (Enrolment);
  • MGFA class IIb to IV;
  • Patient eligible for Ravulizumab treatment based on AIFA reimbursement criteria
  • Vaccination cycle for Neisseria meningitidis completed at least two weeks before Ravulizumab initiation or antibiotics chemoprophylaxis according to the SmPC.

Exclusion criteria

Exclusion Criteria:

  • Patient unable to understand and sign the
  • to the active substance or to any of the of the study product
  • Patient for whom the study product is according to SmPC
  • Previous treatment with C5 inhibitors
  • Last rituximab infusion performed \< 6 months before T-4 (Enrolment)
  • Last infusion with FcRn blockers performed \< 3 months before T-4 (Enrollment)
  • Pregnant or lactating or planning a pregnancy during the study
  • Patient who plan to relocate during the study
  • Patient who are unsure of following the visit schedule
  • Patient unable to complete questionnaires
  • Previous or current participation to other interventional studies
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Ravulizumab

    Participants will receive Ravulizumab until Week 50 ± 14 days after baseline or until discontinuation.

    Drug: Ravulizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Week 50

    Time frame: Week 50

  2. Change From Baseline in MG-ADL Total Score at Week 50

    Time frame: Baseline, Week 50

Secondary outcomes

  1. MG-ADL Total Score at Weeks 2, 10, and 26

    Time frame: Weeks 2, 10, and 26

  2. Change From Baseline in MG-ADL Total Score at Weeks 2, 10 and 26

    Time frame: Baseline, Weeks 2, 10 and 26

  3. Percentage of Participants With >=2- Point Reduction From Baseline in MG-ADL Total Score at Weeks 2, 10, 26, and 50

    Time frame: Baseline, Weeks 2, 10, 26, and 50

  4. Quantitative Myasthenia Gravis (QMG) Total Score at Weeks 2, 10, 26, and 50

    Time frame: Weeks 2, 10, 26, and 50

  5. Change From Baseline in QMG Total Score at Weeks 2, 10, 26 and 50

    Time frame: Baseline, Weeks 2, 10, 26 and 50

  6. Percentage of Participants With >=3- Point Reduction From Baseline in QMG Total Score at Weeks 2, 10, 26, and 50

    Time frame: Baseline, Weeks 2, 10, 26, and 50

  7. Myasthenia Gravis Composite (MGC) Total Score at Weeks 2, 10, 26, and 50

    Time frame: Weeks 2, 10, 26, and 50

  8. Change From Baseline in MGC Total Score at Weeks 2,10, 26 and 50

    Time frame: Baseline, Weeks 2, 10, 26 and 50

  9. Percentage of Participants With >=3- Point Reduction From Baseline in MGC Total Score at Weeks 2, 10, 26 and 50

    Time frame: Baseline, Weeks 2, 10, 26, and 50

  10. Myasthenia Gravis Quality of Life 15-Item Scale - Revised (MG-QoL15r) Total Score at Weeks 10, 26, and 50

    Time frame: Weeks 10, 26, and 50

  11. Change From Baseline in MG-QoL15r Total Score at Weeks 10, 26 and 50

    Time frame: Baseline, Weeks 10, 26 and 50

  12. Hospital Anxiety and Depression Scale (HADS) Total Score at Weeks 10, 26, and 50

    Time frame: Weeks 10, 26, and 50

  13. Change From Baseline in HADS Total Score at Weeks 10, 26 and 50

    Time frame: Baseline, Weeks 10, 26 and 50

  14. Insomnia Severity Index Scale (ISI) Total Score at Weeks 10, 26, and 50

    Time frame: Weeks 10, 26, and 50

  15. Change From Baseline in ISI Total Score at Weeks 10, 26 and 50

    Time frame: Baseline, Weeks 10, 26 and 50

  16. Pain Visual Analogue Scale (Pain VAS) Total Score at Weeks 2, 10, 26, and 50

    Time frame: Weeks 2, 10, 26, and 50

  17. Change From Baseline in Pain VAS Total Score at Weeks 2, 10, 26 and 50

    Time frame: Baseline, Weeks 2, 10, 26 and 50

  18. Percentage of Participants With Mean Dose Reduction From Baseline of Corticosteroids and Immunosuppressants (ISTs) Treatment at Weeks 2, 10, 26, and 50

    Time frame: Baseline, Weeks 2, 10, 26, and 50

  19. Percentage of Participants in Different ISTs Status at Baseline, and at Weeks 2, 10, 26, and 50

    Time frame: Baseline, Weeks 2, 10, 26, and 50

  20. Number of Clinical Deterioration Events

    Time frame: Baseline, Weeks 2, 10, 26, and 50

  21. Percentage of Participants With Minimal Symptom Expression at Weeks 2, 10, 26, and 50

    Time frame: Weeks 2, 10, 26, and 50

  22. Institute For Medical Technology Assessment (iMTA) Productivity Cost Questionnaire (iPCQ) Score at Weeks 10, 26, and 50

    Time frame: Weeks 10, 26, and 50

  23. Change From Baseline in iMTA iPCQ Score at Weeks 10, 26 and 50

    Time frame: Baseline, Weeks 10, 26 and 50

  24. Biomarkers analyses (complement system proteins, interleukins and miRNA serum levels)

    Time frame: Baseline, Week 10, 26, and 50

07

Study locations

9 of 23 sites recruiting
  • Clinical Trial Site
    Bergamo, Italy
    Recruiting
  • Clinical Trial Site
    Bologna, Italy
    Not yet recruiting
  • Clinical Trial Site
    Bologna, Italy
    Recruiting
  • Clinical Trial Site
    Brescia, Italy
    Recruiting
  • Clinical Trial Site
    Florence, Italy
    Recruiting
  • Clinical Trial Site
    Imperia, Italy
    Not yet recruiting
  • Clinical Trial Site
    Lecco, Italy
    Recruiting
  • Clinical Trial Site
    Messina, Italy
    Not yet recruiting
  • Clinical Trial Site
    Milan, Italy
    Recruiting
  • Clinical Trial Site
    Milan, Italy
    Not yet recruiting
  • Clinical Trial Site
    Naples, Italy
    Not yet recruiting
  • Clinical Trial Site
    Novara, Italy
    Not yet recruiting
  • Clinical Trial Site
    Orbassano, Italy
    Not yet recruiting
  • Clinical Trial Site
    Padova, Italy
    Not yet recruiting
  • Clinical Trial Site
    Palermo, Italy
    Not yet recruiting
  • Clinical Trial Site
    Parma, Italy
    Recruiting
  • Clinical Trial Site
    Pavia, Italy
    Not yet recruiting
  • Clinical Trial Site
    Pisa, Italy
    Not yet recruiting
  • Clinical Trial Site
    Roma, Italy
    Not yet recruiting
  • Clinical Trial Site
    Salerno, Italy
    Not yet recruiting
  • Clinical Trial Site
    San Giovanni Rotondo, 71013, Italy
    Recruiting
  • Clinical Trial Site
    Sassari, Italy
    Recruiting
  • Clinical Trial Site
    Torino, Italy
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jun 2027, 22 months after the start.

Of 62 observational studies under Myasthenia Gravis, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 24. This study's planned 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2025
First posted
May 13, 2025
StartActual
Jul 31, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Feb 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06967480
Responsible party
Sponsor
First posted
May 13, 2025
Start date
Jul 31, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Feb 5, 2026

Study contacts

Alexion Pharmaceuticals, Inc. (Sponsor)
Contact
clinicaltrials@alexion.com
1-855-752-2356

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion